ICU Medical (NASDAQ:ICUI) Updates FY 2025 Earnings Guidance

Key Points

• ICU Medical has updated its FY 2025 earnings guidance, projecting earnings per share between $6.850 and $7.15, which exceeds the consensus estimate of $6.637.
• Notable changes in analyst ratings include KeyCorp reducing its price target from $209.00 to $191.00, while Wall Street Zen upgraded its rating from "hold" to "buy".
• ICU Medical’s stock increased by 2.4% on Thursday, reaching a price of $129.91, with a trading volume significantly above its average.

ICU Medical (NASDAQ:ICUI - Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 6.850-7.15 for the period, compared to the consensus earnings per share estimate of 6.637. The company issued revenue guidance of -.

Analysts Set New Price Targets

Several research firms have issued reports on ICUI. KeyCorp reduced their price objective on ICU Medical from $209.00 to $191.00 and set an "overweight" rating on the stock in a report on Monday, April 21st. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a report on Sunday, May 18th. Finally, Raymond James Financial reduced their price objective on ICU Medical from $197.00 to $187.00 and set a "strong-buy" rating on the stock in a report on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, ICU Medical has an average rating of "Buy" and a consensus price target of $192.67.

ICU Medical Trading Up 2.4%

Shares of ICUI stock traded up $3.02 during trading hours on Thursday, reaching $129.91. The company had a trading volume of 435,627 shares, compared to its average volume of 251,820. The company has a 50 day moving average of $130.58 and a 200 day moving average of $140.98. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.59 and a quick ratio of 1.52. The firm has a market cap of $3.20 billion, a price-to-earnings ratio of -33.92 and a beta of 0.88. ICU Medical has a 1-year low of $121.38 and a 1-year high of $196.26.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The medical instruments supplier reported $1.66 earnings per share for the quarter, beating analysts' consensus estimates of $1.44 by $0.22. ICU Medical had a positive return on equity of 6.75% and a negative net margin of 3.87%. On average, equities research analysts anticipate that ICU Medical will post 4.11 EPS for the current year.

Insiders Place Their Bets

In related news, Director David C. Greenberg sold 1,942 shares of the firm's stock in a transaction on Tuesday, May 13th. The stock was sold at an average price of $143.66, for a total transaction of $278,987.72. Following the sale, the director owned 6,760 shares of the company's stock, valued at approximately $971,141.60. This trade represents a 22.32% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, COO Christian B. Voigtlander sold 4,985 shares of the stock in a transaction dated Wednesday, May 28th. The stock was sold at an average price of $128.50, for a total value of $640,572.50. Following the transaction, the chief operating officer owned 6,088 shares of the company's stock, valued at approximately $782,308. This trade represents a 45.02% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 36,097 shares of company stock worth $4,860,156. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ICU Medical

A number of large investors have recently added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in ICU Medical by 32.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 68,211 shares of the medical instruments supplier's stock worth $9,472,000 after purchasing an additional 16,680 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in ICU Medical by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,764 shares of the medical instruments supplier's stock worth $1,772,000 after purchasing an additional 560 shares in the last quarter. Intech Investment Management LLC increased its holdings in ICU Medical by 38.6% during the 1st quarter. Intech Investment Management LLC now owns 11,938 shares of the medical instruments supplier's stock worth $1,658,000 after purchasing an additional 3,326 shares in the last quarter. AQR Capital Management LLC increased its holdings in ICU Medical by 2.5% during the 1st quarter. AQR Capital Management LLC now owns 9,360 shares of the medical instruments supplier's stock worth $1,297,000 after purchasing an additional 229 shares in the last quarter. Finally, United Services Automobile Association bought a new position in ICU Medical during the 1st quarter worth about $218,000. Institutional investors own 96.10% of the company's stock.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.